OS Therapies (NYSE:OSTX) Receives "Buy" Rating from D. Boral Capital

Key Points

• OS Therapies has received a "buy" rating from D. Boral Capital, along with a target price of $20.00 for the stock.
• Recently, OS Therapies' stock traded down 2.6%, reaching $2.25, with a market capitalization of $71.20 million.
• Several large investors have increased their stakes in OS Therapies, with CM Management LLC raising its position by 172.6% in the first quarter.

OS Therapies (NYSE:OSTX - Get Free Report)'s stock had its "buy" rating reiterated by equities research analysts at D. Boral Capital in a note issued to investors on Friday,Benzinga reports. They currently have a $20.00 target price on the stock.

OS Therapies Trading Down 2.6%

OS Therapies stock traded down $0.06 during mid-day trading on Friday, hitting $2.25. 113,712 shares of the company's stock were exchanged, compared to its average volume of 721,655. OS Therapies has a 1-year low of $1.12 and a 1-year high of $7.00. The stock has a 50 day moving average of $1.95 and a two-hundred day moving average of $1.76. The stock has a market cap of $71.20 million and a P/E ratio of -2.85.

Institutional Investors Weigh In On OS Therapies

A number of large investors have recently added to or reduced their stakes in the stock. CM Management LLC raised its position in shares of OS Therapies by 172.6% in the first quarter. CM Management LLC now owns 300,000 shares of the company's stock valued at $462,000 after purchasing an additional 189,956 shares during the period. XTX Topco Ltd bought a new stake in shares of OS Therapies during the 2nd quarter worth $63,000. Finally, Bridgeway Capital Management LLC acquired a new position in OS Therapies in the 2nd quarter valued at $47,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.